line, but with all of the ups and downs (mostly downs) from Amicus ( FOLD ) over the past year, I can understand if investors no longer ..... migalastat could still be viable as part of a combo therapy. Amicus shares could still be worth as much as $4 today, but investors
Redmile Group reports a 15.14% passive stake in Amicus Therapeutics ( FOLD +1.9% ). 13G Post your comment!
Amicus Therapeutics , Inc. ( FOLD ) Strategic Update Conference Call November ..... gentlemen. And welcome to the Amicus Therapeutics Strategic Update Conference Call ..... And thank you for joining Amicus Therapeutics ’ Strategic Update Conference
CNC ) started at Equalweight at Morgan Stanley. Amicus Therapeutics ( FOLD ) cut to Neutral from Buy at Janney. Price target is now $2.50. See also: FOLD revises terms of Glaxo deal, outlines acquisition
Nov 21 (Reuters) - Amicus Therapeutics Inc : * JP Morgan cuts to neutral from overweight For a summary of rating and price target changes on U.S. companies: Reuters
Nov 20 (Reuters) - Amicus Therapeutics Inc : * Leerink Swann cuts target price to $2.50 from $3.00; rating market perform For a summary of rating and price target
Nov 20 (Reuters) - Amicus Therapeutics Inc : * Amicus has acquired Callidus Biopharma * Under deal terms, Callidus Shareholders will get $15 million in shares of co
Nov 20 (Reuters) - Amicus Therapeutics Inc : * Amicus Therapeutics and GSK announce revised fabry agreement * Says acquires full rights to global drug development, regulatory and
(Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...
(Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...